Dianicline is a selective partial agonist of the α4β2 nicotinic acetylcholine receptor and was primarily investigated for its potential in smoking cessation. It works by modulating the release of dopamine in the brain, reducing the rewarding effects of nicotine and helping to alleviate withdrawal symptoms and cravings. Clinical trials explored its efficacy in helping individuals quit smoking by targeting the neurological pathways involved in nicotine dependence. Although it showed initial promise, further development was discontinued due to lack of sufficient efficacy in later-stage trials. Research on dianicline contributed to the understanding of nicotinic receptor targets in addiction treatment.